A phase I study of first-line L-glutamine (Gln) with gemcitabine (gem) and nab-paclitaxel (nab-p) in advanced pancreatic cancer (GlutaPanc)

被引：0
|
作者：
Davelaar, John
Tighiouart, Mourad
Hendifar, Andrew Eugene
Osipov, Arsen
Moshayedi, Natalie
Placencio-Hickok, Veronica
Bhowmick, Neil
Gong, Jun
机构：
[1] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[2] Cedars Sinai Med Ctr, Samuel Oschin Canc Ctr, Los Angeles, CA 90048 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.TPS636
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS636
引用
收藏
页数：3
相关论文
共 50 条
  • [41] HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P plus GEM) for unresectable locally advanced pancreatic cancer (LAPC)
    Tanimoto, A.
    Yagisawa, M.
    Nakano, S.
    Kawamoto, Y.
    Yuki, S.
    Ishiguro, A.
    Takahata, T.
    Sato, A.
    Iwanaga, I.
    Ehira, N.
    Uebayashi, M.
    Muto, O.
    Sasaki, T.
    Hatanaka, K.
    Tateyama, M.
    Wakabayashi, T.
    Dazai, M.
    Minami, S.
    Sakata, Y.
    Komatsu, Y.
    ANNALS OF ONCOLOGY, 2019, 30
  • [42] First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma
    Pat Gulhati
    Laura Prakash
    Matthew H. G. Katz
    Xuemei Wang
    Milind Javle
    Rachna Shroff
    David Fogelman
    Jeffrey E. Lee
    Ching-Wei D. Tzeng
    Jeffrey H. Lee
    Brian Weston
    Eric Tamm
    Priya Bhosale
    Eugene J. Koay
    Anirban Maitra
    Huamin Wang
    Robert A. Wolff
    Gauri R. Varadhachary
    Annals of Surgical Oncology, 2019, 26 : 619 - 627
  • [43] First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma
    Gulhati, Pat
    Prakash, Laura
    Katz, Matthew H. G.
    Wang, Xuemei
    Javle, Milind
    Shroff, Rachna
    Fogelman, David
    Lee, Jeffrey E.
    Tzeng, Ching-Wei D.
    Lee, Jeffrey H.
    Weston, Brian
    Tamm, Eric
    Bhosale, Priya
    Koay, Eugene J.
    Maitra, Anirban
    Wang, Huamin
    Wolff, Robert A.
    Varadhachary, Gauri R.
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (02) : 619 - 627
  • [44] Randomized phase 2 study of nab-paclitaxel and gemcitabine with or without tocilizumab as first-line treatment in patients with advanced pancreatic cancer (PACTO)
    Chen, Inna Markovna
    Johansen, Julia S.
    Theile, Susann
    Madsen, Kasper
    Dajani, Olav
    Lorentzen, Torben
    Zimmers, Teresa
    Nielsen, Dorte
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] A pilot phase II multicenter study of nab-paclitaxel (Nab-P) and gemcitabine (G) as preoperative therapy for potentially resectable pancreatic cancer (PC)
    MacKenzie, Shawn
    Zeh, Herbert
    McCahill, Laurence E.
    Sielaff, Timothy D.
    Bahary, Nathan
    Gribbin, Thomas Edward
    Seng, John E.
    Leach, Joseph W.
    Harmon, Jocelyn
    Demeure, Michael J.
    Von Hoff, Daniel D.
    Moser, A. Jim
    Ramanathan, Ramesh K.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [46] Sindilimab combined with nab-paclitaxel plus gemcitabine as first-line treatment for patients with advanced pancreatic cancer.
    Zhu, Huayun
    Sun, Xiaofeng
    Pan, Xuan
    Wu, Pingping
    Chen, Jia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [47] Phase 1 study of nivolumab (nivo) plus nab-paclitaxel (nab-P) ± gemcitabine (G) in pancreatic cancer (PC): safety evaluation of patients treated with nivo plus nab-P in arm A
    Hochster, Howard S.
    Wainberg, Zev A.
    Gutierrez, Martin
    Waterhouse, David
    Chiorean, E. Gabriela
    George, Ben
    Ko, Amy
    Manax, Victoria
    Stergiopoulos, Sotirios
    O'Dwyer, Peter
    CANCER RESEARCH, 2016, 76
  • [48] Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel
    Riedl, Jakob M.
    Schwarzenbacher, Esther
    Moik, Florian
    Horvath, Lena
    Gantschnigg, Antonia
    Renneberg, Felix
    Posch, Florian
    Barth, Dominik A.
    Stotz, Michael
    Pichler, Martin
    Hatzl, Stefan
    Fandler-Hofler, Simon
    Gressenberger, Paul
    Gary, Thomas
    Jost, Philipp J.
    Greil, Richard
    Ay, Cihan
    Djanani, Angela
    Gerger, Armin
    Schlick, Konstantin
    THROMBOSIS AND HAEMOSTASIS, 2022, 122 (04) : 633 - 645
  • [49] Nab Paclitaxel (Nab-P) and Gemcitabine (G) as first line chemotherapy (CT) in advanced pancreatic cancer (APDAC) patients (pts): An Italian "real life" study
    Giordano, G.
    Febbraro, A.
    Vaccaro, V.
    Zagonel, V.
    De Giorgi, U.
    Melisi, D.
    Vasile, E.
    Bianco, R.
    Lo Re, G.
    Valente, M.
    Formica, V.
    Montesarchio, V.
    Maiorino, L.
    Sanna, G.
    Bittoni, A.
    Ricci, V.
    Santini, D.
    Zaniboni, A.
    Milella, M.
    De Vita, F.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S444 - S444
  • [50] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study
    Yuan Zong
    Jiajia Yuan
    Zhi Peng
    Ming Lu
    Xicheng Wang
    Lin Shen
    Jun Zhou
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 1529 - 1536
12345